IGC PHARMA, INC. Common Stock and Additional Paid-In Capital
IGC PHARMA, INC. (IGC) had Common Stock and Additional Paid-In Capital of $142.06 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Stockholders' Equity Note › Common Stock, Number of Shares, Par Value and Other Disclosure
us-gaap:CommonStocksIncludingAdditionalPaidInCapital · last filed 2026-08-14
- 2026-06-30: Common Stocks, Including Additional Paid in Capital $142.06M.
- 2026-03-31: Common Stocks, Including Additional Paid in Capital $139.12M.
- 2025-12-31: Common Stocks, Including Additional Paid in Capital $138.01M.
- 2025-09-30: Common Stocks, Including Additional Paid in Capital $135.77M.
| Period end | Common Stocks, Including Additional Paid in Capital | Common Stocks, Including Additional Paid in Capital as first filed |
|---|---|---|
| 2026-06-30 | $142.06M 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $139.12M 10-Q · filed 2026-05-15 | |
| 2025-12-31 | $138.01M 10-Q · filed 2026-08-14 | |
| 2025-09-30 | $135.77M 10-Q · filed 2025-11-14 | |
| 2025-06-30 | $131.92M 10-Q · filed 2025-08-14 | |
| 2025-03-31 | $130.57M 10-KT · filed 2026-03-18 | |
| 2024-12-31 | $129.31M 10-Q · filed 2025-02-14 | |
| 2024-09-30 | $128.58M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $127.35M 10-Q · filed 2024-08-07 | |
| 2024-03-31 | $124.41M 10-K · filed 2025-06-27 | |
| 2023-12-31 | $123.26M 10-Q · filed 2024-02-14 | |
| 2023-09-30 | $122.73M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $119.32M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $118.97M 10-K · filed 2024-06-24 | |
| 2022-12-31 | $118.38M 10-Q · filed 2023-02-14 | |
| 2022-09-30 | $117.90M 10-Q · filed 2022-11-01 | |
| 2022-06-30 | $117.17M 10-Q · filed 2022-08-05 | |
| 2022-03-31 | $116.02M 10-K · filed 2023-07-07 | |
| 2021-12-31 | $114.89M 10-Q · filed 2022-02-10 | |
| 2021-09-30 | $114.37M 10-Q · filed 2021-10-29 | |
| 2021-06-30 | $110.53M 10-Q · filed 2021-08-11 | |
| 2021-03-31 | $109.72M 10-K · filed 2022-06-23 | |
| 2020-12-31 | $95.43M 10-Q · filed 2021-02-16 | |
| 2020-09-30 | $95.27M 10-Q · filed 2020-11-20 | |
| 2020-06-30 | $95.02M 10-Q · filed 2020-08-19 | |
| 2020-03-31 | $94.75M 10-K · filed 2021-06-14 | |
| 2019-12-31 | $94.58M 10-Q · filed 2020-02-10 | |
| 2019-09-30 | $94.39M 10-Q · filed 2019-11-06 | |
| 2019-06-30 | $94.25M 10-Q · filed 2019-08-09 | |
| 2019-03-31 | $94.04M 10-K · filed 2020-07-13 | |
| 2018-12-31 | $95.33M 10-Q · filed 2019-02-12 | |
| 2018-03-31 | $63.92M 10-K · filed 2019-06-14 | $63.92M 10-K · filed 2018-06-21 |
| 2017-03-31 | $61.42M 10-K · filed 2018-06-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |